BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25209056)

  • 1. Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community.
    Penn DC; Chang Y; Meyer AM; DeFilippo Mack C; Sanoff HK; Stitzenberg KB; Carpenter WR
    Cancer; 2015 Jan; 121(1):93-101. PubMed ID: 25209056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
    Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
    Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation.
    Carpenter WR; Meyer AM; Wu Y; Qaqish B; Sanoff HK; Goldberg RM; Weiner BJ
    Med Care; 2012 Aug; 50(8):737-48. PubMed ID: 22437624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer.
    Tan HJ; Meyer AM; Kuo TM; Smith AB; Wheeler SB; Carpenter WR; Nielsen ME
    Cancer; 2015 Mar; 121(6):836-43. PubMed ID: 25410684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
    Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
    Sanoff HK; Carpenter WR; Stürmer T; Goldberg RM; Martin CF; Fine JP; McCleary NJ; Meyerhardt JA; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Clin Oncol; 2012 Jul; 30(21):2624-34. PubMed ID: 22665536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial/ethnic disparities in the adjuvant chemotherapy of locally advanced colon cancer patients.
    Zhong X; Guo Z; Gao P; Song Y; Sun J; Chen X; Sun Y; Wang Z
    J Surg Res; 2018 Aug; 228():27-34. PubMed ID: 29907221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why providers participate in clinical trials: considering the National Cancer Institute's Community Clinical Oncology Program.
    McAlearney AS; Song PH; Reiter KL
    Contemp Clin Trials; 2012 Nov; 33(6):1143-9. PubMed ID: 22925970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation.
    Davidoff AJ; Rapp T; Onukwugha E; Zuckerman IH; Hanna N; Pandya N; Mullins CD
    Med Care; 2009 Dec; 47(12):1229-36. PubMed ID: 19786906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of race and health insurance in treatment disparities of colon cancer: A retrospective analysis utilizing a national population database in the United States.
    Hao S; Snyder RA; Irish W; Parikh AA
    PLoS Med; 2021 Oct; 18(10):e1003842. PubMed ID: 34695123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of access to chemotherapy for colon cancer: multiplicative disadvantage of being extremely poor, inadequately insured and African American.
    Gorey KM; Haji-Jama S; Bartfay E; Luginaah IN; Wright FC; Kanjeekal SM
    BMC Health Serv Res; 2014 Mar; 14():133. PubMed ID: 24655931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provider-based research networks demonstrate greater hospice use for minority patients with lung cancer.
    Penn DC; Stitzenberg KB; Cobran EK; Godley PA
    J Oncol Pract; 2014 Jul; 10(4):e182-90. PubMed ID: 24781367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A method for analyzing the business case for provider participation in the National Cancer Institute's Community Clinical Oncology Program and similar federally funded, provider-based research networks.
    Reiter KL; Song PH; Minasian L; Good M; Weiner BJ; McAlearney AS
    Cancer; 2012 Sep; 118(17):4253-61. PubMed ID: 22213241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study.
    Lai Y; Wang C; Civan JM; Palazzo JP; Ye Z; Hyslop T; Lin J; Myers RE; Li B; Jiang B; Sama A; Xing J; Yang H
    Gastroenterology; 2016 May; 150(5):1135-1146. PubMed ID: 26836586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential receipt of sentinel lymph node biopsy within practice-based research networks.
    Meyer AM; Reeder-Hayes KE; Liu H; Wheeler SB; Penn D; Weiner BJ; Carpenter WR
    Med Care; 2013 Sep; 51(9):812-8. PubMed ID: 23942221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy.
    Mack CD; Glynn RJ; Brookhart MA; Carpenter WR; Meyer AM; Sandler RS; Stürmer T
    Pharmacoepidemiol Drug Saf; 2013 Aug; 22(8):810-8. PubMed ID: 23296544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer.
    Murphy CC; Harlan LC; Warren JL; Geiger AM
    J Clin Oncol; 2015 Aug; 33(23):2530-6. PubMed ID: 26150445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
    Sanoff HK; Carpenter WR; Freburger J; Li L; Chen K; Zullig LL; Goldberg RM; Schymura MJ; Schrag D
    Cancer; 2012 Sep; 118(17):4309-20. PubMed ID: 22294436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Explaining black-white differences in receipt of recommended colon cancer treatment.
    Baldwin LM; Dobie SA; Billingsley K; Cai Y; Wright GE; Dominitz JA; Barlow W; Warren JL; Taplin SH
    J Natl Cancer Inst; 2005 Aug; 97(16):1211-20. PubMed ID: 16106026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.